Obesity is known to have important roles in driving prostate cancer aggressiveness and
increased mortality. Multiple mechanisms have been postulated for these clinical …

Prostate cancer (PCa) accounts for a high number of deaths in males with no available
curative treatments. Patients with PCa are commonly diagnosed in advanced stages due to …

With advances in the discovery of the clinical and molecular landscapes of prostate cancer
(PCa), implementation of precision medicine-guided therapeutic testing in the clinic has …

Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new
perspective in light of the recent advances in research. Although classical NEPC is rarely …

Understanding the intricacies of lethal prostate cancer poses specific challenges due to
difficulties in accurate modeling of metastasis in vivo. Here we show that NPK EYFP mice …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Background Immune checkpoint inhibitor monotherapy in metastatic castration-resistant
prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be …

PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated
potential in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here …

Background Castration-resistant prostate cancer (CRPC) is a major cause of recurrence and
mortality among prostate cancer (PCa) patients. Myeloid-derived suppressor cells (MDSCs) …

Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants
(AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of …